• Je něco špatně v tomto záznamu ?

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

A. Cuneo, G. Follows, GM. Rigolin, A. Piciocchi, A. Tedeschi, L. Trentin, AM. Perez, M. Coscia, L. Laurenti, G. Musuraca, L. Farina, AR. Delgado, EM. Orlandi, P. Galieni, FR. Mauro, C. Visco, A. Amendola, A. Billio, R. Marasca, A. Chiarenza, V....

. 2018 ; 103 (7) : 1209-1217. [pub] 20180419

Jazyk angličtina Země Itálie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035292

We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion.

Department of Hematology Hospital Clinic Institut Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain

Department of Hematology University Hospital Hradec Kralove Czech Republic

Division of Experimental Oncology IRCCS San Raffaele Scientific Institute and Vita Salute San Raffaele University Milan Italy

Haematology Department University Hospital National Health Service Trust Southampton UK

Hematology and Cellular Therapy Ospedale C e G Mazzoni Ascoli Piceno Italy

Hematology and Clinical Immunology Department of Medicine University of Padua Italy

Hematology and Transplant Unit San Maurizio Hospital Azienda Sanitaria dell'Alto Adige Bolzano Italy

Hematology Department Fondazione IRCCS Istituto Nazionale Tumori Milano Italy

Hematology Department of Biomedical Sciences and Hematology Sapienza University Rome Italy

Hematology Department of Cell Therapy and Hematology University Hospital Verona Italy

Hematology Department of Medical Sciences St Anna University Hospital Ferrara Italy

Hematology DIMECS e Dipartimento Oncologico Università del Piemonte Orientale Amedeo Avogadro Novara Italy

Hematology Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy

Hematology San Bortolo Hospital Vicenza Italy

Hematology San Carlo Hospital Potenza Italy

Hematology Unit A Pugliese Hospital Azienda Ospedaliera Pugliese Ciaccio Catanzaro Italy

Hematology Unit Arcispedale S Maria Nuova Reggio Emilia Italy

Hematology Unit Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele Catania Italy

Hematology Unit Careggi Hospital Florence Italy

Hematology Unit Città della Salute e della Scienza University of Turin Italy

Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan Italy

Hematology Unit Fondazione IRCCS Policlinico San Matteo Pavia Italy

Hematology Unit Hospital Universitario 12 de Octubre Madrid Spain

Hematology Unit Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS Meldola Italy

Hematology Unit University Hospital Modena Italy

Hematology Università Cattolica del Sacro Cuore Policlinico A Gemelli Rome Italy

Hematology University Hospital IBSAL and CIBERONC Salamanca Spain

Hematology University Hospital Parma Italy

Hospital Costa del Sol Marbella Málaga Spain

Hospital de la Santa Creu i Sant Pau Barcellona Spain

Italian Group for Adult Hematologic Diseases Data Center and Health Outcomes Research Unit Rome Italy

Norwich Medical School UK

Oncology Unit Cardinal Massaia Hospital Asti Italy

Oxford University Hospitals NHS Foundation Trust UK

UK CLL Forum Cambridge University Hospitals NHS Foundation Trust UK

UK CLL Forum Oxford University Hospitals NHS Foundation Trust UK

University Hospitals of Leicester NHS Trust UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035292
003      
CZ-PrNML
005      
20240516084354.0
007      
ta
008      
191007s2018 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.189837 $2 doi
035    __
$a (PubMed)29674504
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Cuneo, Antonio $u Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy cut@unife.it.
245    10
$a Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study / $c A. Cuneo, G. Follows, GM. Rigolin, A. Piciocchi, A. Tedeschi, L. Trentin, AM. Perez, M. Coscia, L. Laurenti, G. Musuraca, L. Farina, AR. Delgado, EM. Orlandi, P. Galieni, FR. Mauro, C. Visco, A. Amendola, A. Billio, R. Marasca, A. Chiarenza, V. Meneghini, F. Ilariucci, M. Marchetti, S. Molica, F. Re, G. Gaidano, M. Gonzalez, F. Forconi, S. Ciolli, A. Cortelezzi, M. Montillo, L. Smolej, A. Schuh, TA. Eyre, B. Kennedy, KM. Bowles, M. Vignetti, J. de la Serna, C. Moreno, R. Foà, P. Ghia, GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum,
520    9_
$a We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x mortalita $7 D015451
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a záchranná terapie $7 D016879
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Itálie $7 D007558
651    _2
$a Spojené království $7 D006113
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Follows, George $u UK CLL Forum, Cambridge University Hospitals NHS Foundation Trust, UK.
700    1_
$a Rigolin, Gian Matteo $u Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
700    1_
$a Piciocchi, Alfonso $u Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
700    1_
$a Tedeschi, Alessandra $u Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
700    1_
$a Trentin, Livio $u Hematology and Clinical Immunology, Department of Medicine, University of Padua, Italy.
700    1_
$a Perez, Angeles Medina $u Hospital Costa del Sol, Marbella, Málaga, Spain.
700    1_
$a Coscia, Marta $u Hematology Unit, Città della Salute e della Scienza, University of Turin, Italy.
700    1_
$a Laurenti, Luca $u Hematology, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy.
700    1_
$a Musuraca, Gerardo $u Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
700    1_
$a Farina, Lucia $u Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
700    1_
$a Delgado, Alfredo Rivas $u Department of Hematology, Hospital Clinic, Institut Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
700    1_
$a Orlandi, Ester Maria $u Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
700    1_
$a Galieni, Piero $u Hematology and Cellular Therapy, "Ospedale C. e G. Mazzoni", Ascoli Piceno, Italy.
700    1_
$a Mauro, Francesca Romana $u Hematology, Department of Biomedical Sciences and Hematology, "Sapienza" University, Rome, Italy.
700    1_
$a Visco, Carlo $u Hematology, San Bortolo Hospital, Vicenza, Italy.
700    1_
$a Amendola, Angela $u Hematology, San Carlo Hospital, Potenza, Italy.
700    1_
$a Billio, Atto $u Hematology and Transplant Unit, San Maurizio Hospital, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy.
700    1_
$a Marasca, Roberto $u Hematology Unit, University Hospital, Modena, Italy.
700    1_
$a Chiarenza, Annalisa $u Hematology Unit, Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy.
700    1_
$a Meneghini, Vittorio $u Hematology, Department of Cell Therapy and Hematology, University Hospital, Verona, Italy.
700    1_
$a Ilariucci, Fiorella $u Hematology Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
700    1_
$a Marchetti, Monia $u Oncology Unit, Cardinal Massaia Hospital, Asti, Italy.
700    1_
$a Molica, Stefano $u Hematology Unit, A. Pugliese Hospital, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy.
700    1_
$a Re, Francesca $u Hematology, University Hospital, Parma, Italy.
700    1_
$a Gaidano, Gianluca $u Hematology, DIMECS e Dipartimento Oncologico, Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy.
700    1_
$a Gonzalez, Marcos $u Hematology, University Hospital-IBSAL and CIBERONC, Salamanca, Spain.
700    1_
$a Forconi, Francesco $u Haematology Department, University Hospital National Health Service Trust, Southampton, UK.
700    1_
$a Ciolli, Stefania $u Hematology Unit, Careggi Hospital, Florence, Italy.
700    1_
$a Cortelezzi, Agostino $u Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Italy.
700    1_
$a Montillo, Marco $u Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
700    1_
$a Smolej, Lukas $u Department of Hematology, University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Schuh, Anna $u UK CLL Forum, Oxford University Hospitals NHS Foundation Trust, UK.
700    1_
$a Eyre, Toby A $u Oxford University Hospitals NHS Foundation Trust, UK.
700    1_
$a Kennedy, Ben $u University Hospitals of Leicester NHS Trust, UK.
700    1_
$a Bowles, Kris M $u Norwich Medical School, UK.
700    1_
$a Vignetti, Marco $u Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
700    1_
$a de la Serna, Javier $u Hematology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
700    1_
$a Moreno, Carol $u Hospital de la Santa Creu i Sant Pau, Barcellona, Spain.
700    1_
$a Foa, Robin $u Hematology, Department of Biomedical Sciences and Hematology, "Sapienza" University, Rome, Italy. $7 xx0317383
700    1_
$a Ghia, Paolo $u Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
710    2_
$a GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 7 (2018), s. 1209-1217
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29674504 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20240516084348 $b ABA008
999    __
$a ok $b bmc $g 1451952 $s 1073842
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 103 $c 7 $d 1209-1217 $e 20180419 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace